Navigation Links
Cholesterol-lowering drug shrinks enlarged prostates in hamster model
Date:10/21/2010

Boston, Mass. - A cholesterol-lowering drug reduced the enlarged prostates of hamsters to the same extent as a drug commonly used to treat benign prostatic hyperplasia (BPH), report researchers at Children's Hospital Boston and their colleagues in the October issue of the Journal of Urology. Together, the drugs worked even better.

"We don't know the mechanism, but the results suggest to us that lowering cholesterol has the potential to reduce BPH in men," says senior author Keith Solomon, PhD, a biochemist, and member of the departments of Orthopaedic Surgery and Urology at Children's. "This brings up the possibility that other cholesterol lowering therapies, including exercise and diet, may prevent BPH from developing."

For unknown reasons, about half of men older than 50 (and 80 percent of men aged 80) develop BPH, most often evident as enlargement of the prostate. BPH leads to difficult urination, urgency, pain, and other symptoms that can cause significant reduction in the quality of life. In advanced stages, BPH can lead to renal failure. Standard medical and surgical treatments typically target the prostate and usually result in a reduction of symptoms but not without significant side effects in some men, Solomon said.

The study implicates circulating cholesterol in the progression of the condition and suggests a potential new strategy for prevention and treatment. The latest findings emerge from experiments with a strain of Syrian hamsters that undergo prostate enlargement naturally.

Led by first author Kristine Pelton, the team tested ezetimibe, an FDA-approved hypercholesterolemic drug (Zetia; Merck) against finasteride (Proscar, Propecia; Merck), a standard therapy for the treatment of BPH. Ezetimibe reduced prostatic enlargement in aged hamsters as effectively as finasteride and combining the two drugs worked better than either one alone.

In an unexpected finding, pathologist and co-author Dolores Di Vizio, MD, PhD, observed that finasteride caused atrophy of the hamster prostate while ezetimibe did not. "These findings provide strong evidence that the cholesterol-lowering drug inhibits BPH by a novel mechanism," said co-author Michael R. Freeman, PhD, professor of Surgery and director of urologic research at Children's Hospital.

The potentially therapeutic effect of cholesterol-lowering on enlarged prostates was pioneered 40 years earlier by co-author Carl Schaffner, PhD, professor emeritus at Rutgers University, who reported similar results in pre-clinical models using a different cholesterol-lowering drug.

"There is a lot more we want to do in the lab, with regards to studying BPH and the use of cholesterol-based therapies to control disease progression," says Solomon.

For example, the researchers want to test lower doses of ezetimibe and finasteride to examine whether the condition can be reversed with fewer side effects. They also want to assess prophylactic cholesterol lowering to determine if the enlargement can be prevented, and whether genes and proteins mediating the effect of cholesterol on the prostate can be identified. "We really want to be in the position to help conduct a clinical trial to test whether this therapy might have efficacy in human patients," Solomon said.

The study also validated the hamster strain as a good preclinical model for testing novel BPH therapies. "The preclinical models for BPH are few, require substantial manipulation or have an unpredictable disease course," Solomon says. "The Syrian hamster model that we are now using seems particularly good for examining the role of cholesterol in prostate disease, and the testing of novel drug therapies to help alleviate symptoms. We should be able to make substantial progress in developing new treatments and in understanding the molecular mechanisms underpinning the disease using these hamsters."


'/>"/>

Contact: Keri Stedman
keri.stedman@childrens.harvard.edu
617-919-3110
Children's Hospital Boston
Source:Eurekalert

Related medicine news :

1. VCU study: Researchers discover a drug combination that shrinks tumors in vivo
2. As girth grows, risk of sudden cardiac death shrinks
3. Drug for advanced kidney cancer shrinks tumors prior to surgery
4. Combination therapy more effective for enlarged prostate
5. Virginia Bioinformatics Institute to model immune responses to gut pathogens
6. New Medicare model guidelines for benefit years 2012-2014 in development
7. Disease transmission model says media coverage cuts infection rate and pandemic extent
8. New model may simplify high-dose radiosurgery planning
9. Treatment for S. aureus skin infection works in mouse model
10. Rheumatoid arthritis signaling protein reverses Alzheimers disease in mouse model
11. Scientists develop the first model for investigating the origins of testicular cancer in humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... "As a doctor of lung medicine ... catheters available on the market," said an inventor from Center Valley, Pa. "My idea ... the patient." , He developed the patent-pending PLEURAL SAFE-t-STAT CATHETER KIT to offer an ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... and financial planning services to communities in the greater Birmingham area, is joining ... resources to underprivileged young people in the region. , The Chris Hammond Youth ...
(Date:7/21/2017)... ... ... Bernard R. Bach, Jr., MD, orthopaedic surgeon at Rush University Medical Center ... Medicine (AOSSM) , received the 2017 Robert E. Leach Sports Medicine Leadership award on ... award is given annually to honor those who have made a significant contribution to ...
(Date:7/21/2017)... ST. LOUIS, MO (PRWEB) , ... July 21, 2017 , ... ... are born knowing how to tie their shoes,” says Suzanne Tucker, Founder of St. ... created the Time-In Toolkit, which launches on Kickstarter on Monday, July 21st. , ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... concussion rates are on the rise, say researchers presenting their work at the ... Ontario, Canada. , “The combination of evaluating the patterns of change in concussion ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... CARLSBAD, Calif. , July 10, 2017  The ... in Boston, MA at the ... unequaled value and unparalleled access to global decision makers ... to draw 800+ life science leaders during two impactful ... Boston, and provides delegates with additional networking opportunities with ...
(Date:7/5/2017)... England , July 5, 2017 Wolfmet ... perfect answer as physics and manufacturing combine to progress molecular ... thyroid, existing SPECT systems are unable to accurately quantify the ... only limited information regarding the success of this radiotherapy treatment ... ...
(Date:7/5/2017)... , July 5, 2017   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade cell ... freeze media ("BioLife"), today announced that it has ... debt holder and largest shareholder, to modify its existing ... Pursuant to the modification, WAVI agreed to exchange its ...
Breaking Medicine Technology: